Supernus Pharmaceuticals Income After Taxes 2011-2024 | SUPN
Supernus Pharmaceuticals income after taxes from 2011 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Supernus Pharmaceuticals Annual Income After Taxes
(Millions of US $) |
| 2023 |
$1 |
| 2022 |
$61 |
| 2021 |
$53 |
| 2020 |
$127 |
| 2019 |
$113 |
| 2018 |
$111 |
| 2017 |
$57 |
| 2016 |
$91 |
| 2015 |
$14 |
| 2014 |
$-11 |
| 2013 |
$-92 |
| 2012 |
$-46 |
| 2011 |
$-23 |
| 2010 |
$-39 |
Supernus Pharmaceuticals Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$20 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$-16 |
| 2023-06-30 |
$-1 |
| 2023-03-31 |
$17 |
| 2022-12-31 |
$25 |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$26 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$22 |
| 2021-06-30 |
$24 |
| 2021-03-31 |
$6 |
| 2020-12-31 |
$31 |
| 2020-09-30 |
$40 |
| 2020-06-30 |
$35 |
| 2020-03-31 |
$22 |
| 2019-12-31 |
$33 |
| 2019-09-30 |
$29 |
| 2019-06-30 |
$33 |
| 2019-03-31 |
$18 |
| 2018-12-31 |
$26 |
| 2018-09-30 |
$28 |
| 2018-06-30 |
$31 |
| 2018-03-31 |
$26 |
| 2017-12-31 |
$14 |
| 2017-09-30 |
$16 |
| 2017-06-30 |
$17 |
| 2017-03-31 |
$10 |
| 2016-12-31 |
$14 |
| 2016-09-30 |
$62 |
| 2016-06-30 |
$10 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$7 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$4 |
| 2014-09-30 |
$-2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$-16 |
| 2013-12-31 |
$-22 |
| 2013-09-30 |
$-24 |
| 2013-06-30 |
$-27 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-14 |
| 2012-09-30 |
$-13 |
| 2012-06-30 |
$-10 |
| 2012-03-31 |
$-9 |
| 2011-12-31 |
$6 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-9 |
| 2011-03-31 |
$-10 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.771B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
